Corvus Pharmaceuticals to Present at the Jefferies 2019 Global Healthcare Conference
A webcast of the presentation will be available live and for 90 days following the event. The webcast may be accessed via the investor relations section of the Corvus website.
About
Corvus Pharmaceuticals is a clinical-stage biopharmaceutical company focused on the development and commercialization of precisely targeted oncology therapies. Corvus’ lead product candidate, ciforadenant (CPI-444), a small molecule inhibitor of the A2A receptor, is currently being evaluated in a multicenter amended Phase 1b/2 clinical trial in patients with various solid tumors. This successive expansion cohort trial is examining the activity of ciforadenant both as a single agent and in combination with Genentech’s atezolizumab, an anti-PD-L1 antibody. Corvus is conducting the trial with Genentech, a member of the Roche Group, under a clinical trial collaboration the two companies entered into in October 2015. In May 2017, Corvus and Genentech expanded the collaboration and are now conducting a trial of ciforadenant and atezolizumab in patients with non-small cell lung cancer (NSCLC) who have failed prior therapies with anti-PD-(L)1 and platinum-based chemotherapy. Corvus is evaluating two additional product candidates: CPI-006, a humanized monoclonal antibody directed against CD73, in a multicenter Phase 1/1b clinical trial in patients with various solid tumors, and CPI-818, an oral, small molecule drug that has been shown to selectively inhibit ITK, in a multicenter Phase 1/1b clinical trial in patients with several types of T-cell lymphomas. For more information, visit www.corvuspharma.com.
INVESTOR CONTACT:
Chief Financial Officer
650-900-4522
LLea@corvuspharma.com
MEDIA CONTACT:
W2O pure
213-262-9390
sseapy@w2ogroup.com
Source: Corvus Pharmaceuticals, Inc.